<DOC>
	<DOCNO>NCT02145403</DOCNO>
	<brief_summary>The investigator hypothesize add carfilzomib standard condition regimen allo-HCT advance high-risk hematologic malignancy decrease post-transplant relapse treatment-related mortality decrease severe GVHD , lead overall improvement transplant outcome .</brief_summary>
	<brief_title>Phase 1/2 Study Carfilzomib Prevention Relapse GVHD Allo-HCT Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Lymphoid Myeloid malignancy require allogeneic hematopoietic cell transplantation Pathology review study institution require Prior highdose chemotherapy autologous HCT ( ) ( ) allow Disease status : Stable disease good time enrollment Age : &gt; 18 &lt; 70 year old time transplant ( &lt; 71 year transplant admission ) Life expectancy ≥ 6 month transplant A 8/8 7/8 HLAmatched donor available Karnofsky Performance Status &gt; 70 % ( A measure quality life range 0 100 100 equal perfect health 0 death . ) Adequate cardiac [ LVEF ( Left Ventricular Ejection Fraction ) &gt; 0.4 ] , pulmonary [ FEV1 ( Forced Expiratory Volume 1 Second ) , FVC ( Forced Vital Capacity ) , correct DLCO ( Diffusing Capacity ) ≥ 50 % predict ] , hepatic [ DB ( Direct Bilirubin ) &lt; 1.5xULN , AST ( Aspartate Aminotransferase ) / ALT ( Alanine transaminase ) ≤3xULN ] renal function [ GFR ( Glomerular Filtration Rate ) ≥ 60 mL/min/1.73 m2 ] Progressive disease Active central nervous system involvement malignancy Non compliance medication medical instruction Lack appropriate caregiver Life expectancy &lt; 6 month Pregnant lactate female Uncontrolled infection require active treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day HIV1/HIV2 HTLV1/HTLV2 seropositivity Active hepatitis A , B C infection Unstable angina myocardial infarction within 6 month prior randomization , NYHA Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , uncontrolled persistent atrial fibrillation/flutter , history ventricular fibrillation , ventricular tachycardia/torsade de pointes , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker History pulmonary hypertension Uncontrolled hypertension uncontrolled diabetes mellitus Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen ( PSA ) level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) Contraindication require concomitant drug supportive treatment , include hypersensitivity available antimicrobial drug intolerance IV hydration due preexist pulmonary cardiac impairment Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior admission Uncontrolled psychiatric condition Any clinically significant medical psychiatric disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Carfilzomib</keyword>
	<keyword>Relapse</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
</DOC>